Epidural @entity3652 in post XXXX -related @entity1118 .

@entity1 @entity2682 @entity3391 @entity3652 @entity158 @entity1566 @entity1118 @entity9
AIM: This study was to identify the safety and efficacy of adding epidural @entity3391 receptor antagonists ( @entity3652 ) to oral @entity2682 for the treatment of post @entity1566 -related @entity1118 . MATERIALS AND METHODS: Forty @entity1 in the age range of 18-50 years with a diagnosis of @entity9 secondary to @entity1566 were randomized into two equal groups. Group I received 0.2 mg/Kg of preservative-free @entity3652 (2 ml) single bolus epidural injection and @entity2682 300 mg three times daily. Group II received isotonic saline 0.9% (2 ml) single bolus epidural injection and @entity2682 300 mg three times daily. @entity158 scores were evaluated pre-injection, 7, 15, 30,45 and 60 days post injection. @entity1 were asked about any side-effects occurred during follow-up period. RESULTS: At all time points examined, @entity158 scores were significantly lower in both groups than pre-injection values (P < 0.0001). @entity158 scores were significantly lower in Group I than in Group II at 7, 15, 30 days after injection (P 0.02, < 0.0001, =0.0001 respectively), but no statistically significant difference was detected between groups at 45, 60 days post injection (P = 0.54, =0.25), there was no statistically significant difference regarding incidence of side-effects in both groups. CONCLUSION: Epidurally administrated @entity3652 seems to be a safe adjunct to @entity2682 in post @entity1566 -related @entity1118 . However, its analgesic efficacy was limited to 30 days after injection.
